Large-cap Health Care company Vertex Pharmaceuticals has moved 1.8% so far today on a volume of 1,252,936, compared to its average of 1,218,241. In contrast, the S&P 500 index moved 0.0%.
Vertex Pharmaceuticals trades -4.15% away from its average analyst target price of $371.72 per share. The 25 analysts following the stock have set target prices ranging from $301.63 to $423.21, and on average have given Vertex Pharmaceuticals a rating of buy.
If you are considering an investment in VRTX, you'll want to know the following:
-
Vertex Pharmaceuticals's current price is 159.0% above its Graham number of $137.55, which implies that at its current valuation it does not offer a margin of safety
-
Vertex Pharmaceuticals has moved 11.4% over the last year, and the S&P 500 logged a change of 15.4%
-
Based on its trailing earnings per share of 13.31, Vertex Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of 26.8 while the S&P 500 average is 15.97
-
VRTX has a forward P/E ratio of 23.2 based on its forward 12 month price to earnings (EPS) of $15.35 per share
-
The company has a price to earnings growth (PEG) ratio of 2.34 — a number near or below 1 signifying that Vertex Pharmaceuticals is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 5.56 compared to its sector average of 4.08
-
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
-
Based in Boston, the company has 4,800 full time employees and a market cap of $91.81 Billion.